Pancreatic cancer news: a readable guide to a clinical trial testing a novel strategy against a longstanding hard-to-target tumor vulnerability and its implications.
Key Takeaways
- Drug daraxonrasib directly targets KRAS-mutant pancreatic tumors
- Treatment nearly doubled median survival and reduced mortality risk by about 60%
- Randomized trial compared daraxonrasib to standard chemotherapy in previously treated metastatic patients